Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100)...
20 insider purchases on record · latest filing 2025-03-26.
Insiders have also filed 8 sale transactions at XCUR.